Drugs / GM-1020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06309277 | Feb 2024 → Mar 2025 | major depressive disorder | Gilgamesh Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM-1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06309277 ↗ |
| Action | Inhibit | “N-methyl-D-aspartate (NMDA) receptor antagonist” NCT06309277 ↗ |
| Route | Oral | “GM-1020 (oral)” NCT06309277 ↗ |